Mr. John L. Higgins

• 
  www.contractpharma.com/news/2008/09/25/ligand_to_buy_ph - [Cached Version]
  Published on: 9/25/2008    Last Visited: 9/25/2008  

  "We are very excited about combining Pharmacopeia with Ligand," said John L. Higgins, president and chief executive officer of Ligand.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=71033 - [Cached Version]
  Published on: 9/25/2007    Last Visited: 9/26/2007  

  SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that John L. Higgins, President and CEO along with the executive management team and Board of Directors will ring the NASDAQ stock market opening bell on Wednesday, September 26 at 9:30 a.m. EDT."We are thrilled to open the NASDAQ bell as it represents the launch of the new Ligand.I would like to recognize the Ligand employees for their hard work and dedication to rebuilding the business and to our shareholders for their continued support," said John L. Higgins.

• 
  www.crmz.com/Report/ReportPreview.asp?BusinessId=13258 - [Cached Version]
  Published on: 6/15/2008    Last Visited: 6/15/2008  

  John L. Higgins
  Chief Executive Officer, President, Director
  Ligand Pharmaceuticals Inc.

• 
  www.sec.gov/Archives/edgar/data/1004960/0000950134-06-0 - [Cached Version]
  Published on: 7/25/2006    Last Visited: 7/26/2006  

  John L. Higgins
  ...
  John Higgins joined Connetics as Chief Financial Officer in 1997, and has served as Executive Vice President, Finance and Administration and Corporate Development since January 2002.He served as Executive Vice President, Finance and Administration, from January 2000 to December 2001, and as Vice President, Finance and Administration from September 1997 through December 1999.Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals, Inc.Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co.Inc., an investment banking firm.He currently serves as a director of BioCryst and a private company.He received his A.B. from Colgate University.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=64560 - [Cached Version]
  Published on: 7/27/2007    Last Visited: 7/27/2007  

  Ligand has gone through significant changes this year, and we have expanded the content and redesigned the functionality of the Web site to reflect our new business strategy and opportunities," said John L. Higgins, President and CEO.

• 
  investors.ligand.com/releasedetail.cfm?ReleaseID=237783 - [Cached Version]
  Published on: 3/21/2007    Last Visited: 8/11/2007  

  "Our strategy of building a highly focused R&D- and royalty-driven biotech company allows us the ability to deliver value to shareholders through this one-time cash dividend and open market share repurchases, while maintaining a strong balance sheet and funding ongoing operations," said John L. Higgins, President and Chief Executive Officer.
  ...
  John L. Higgins, President and CEO or

• 
  www.biospace.com/news_story.aspx?NewsEntityId=110940&So - [Cached Version]
  Published on: 9/25/2008    Last Visited: 9/25/2008  

  "We are very excited about combining Pharmacopeia with Ligand," said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.
  ...
  Mr. Higgins provided the following strategic and operating rationale for the proposed acquisition of Pharmacopeia:
  ...
  "We are impressed with the quality of Pharmacopeia's drug partnerships," Mr. Higgins continued.
  ...
  Ligand Pharmaceuticals Incorporated John L. Higgins, President and CEO Erika Luib, Investor Relations 858-550-7896 or Lippert/Heilshorn & Associates Don Markley dmarkley@lhai.com 310-691-7100 or Pharmacopeia, Inc.

• 
  biz.yahoo.com/bw/080924/20080924006241.html?.v=1 - [Cached Version]
  Published on: 9/24/2008    Last Visited: 9/24/2008  

  "We are very excited about combining Pharmacopeia with Ligand," said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.
  ...
  Mr. Higgins provided the following strategic and operating rationale for the proposed acquisition of Pharmacopeia:
  ...
  "We are impressed with the quality of Pharmacopeia's drug partnerships," Mr. Higgins continued.
  ...
  Contact:Ligand Pharmaceuticals Incorporated John L. Higgins, President and CEO

• 
  www.tmcnet.com/usubmit/2008/09/26/3672480.htm - [Cached Version]
  Published on: 9/25/2008    Last Visited: 9/26/2008  

  John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.

• 
  investors.ligand.com/releasedetail.cfm?ReleaseID=233126 - [Cached Version]
  Published on: 3/1/2007    Last Visited: 8/11/2007  

  SAN DIEGO--(BUSINESS WIRE)--March 1, 2007--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the appointment of John L. Higgins, David M. Knott, Elizabeth M. Greetham and Todd C. Davis to its board of directors.
  ...
  The company will also benefit from the leadership and experience of Dr. Kozarich in his expanded role as our new Chairman," said John L. Higgins, President and Chief Executive Officer.
  ...
  John L. Higgins, President and CEO

Page:  1 2 3 4 5